SecBot SecBot

BMEA

Biomea Fusion, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001840439 Biotech & Drug Discovery
$0.6251 −0.01 (−1.71%)
Oct 27 4:00 PM ET · prev $0.6360
Market cap
$42.4M
Nano cap
Consensus
Buy
85% Buy or better · 13 analysts
Median target
$6.00
+860% · range $4.00–10.00
Next earnings
Nov 3
in 7 days · EPS est. −$0.22
1 year
−56.0%
from $1.42 · Oct 27
30 days
−51.5%
from $1.29
52-week range
$0.5850–2.21
−72% from high · low Oct 22
Avg volume 20D
2.70M
Oct 14 spike 11.71M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 2 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/5 ·Next Earnings date, Nov 3, 2026
Strongest BULLISH Biomea Fusion reported Phase 1 topline data for BMF-650, its next-generation oral GLP-1 receptor agonist for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 6 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    11 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.270 → −$0.220 over 90 days. 2 up, 0 down in 30 days.

  • TrendDOWNTREND

    55% below its 50-day average. New closing low $0.5850 on Oct 22.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 14.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADATRIM99—
MARSHALL WACE, LLPADD2,049,802$3.0M
GEODE CAPITAL MANAGEMENT, LLCADD708,854$1.0M
JANE STREET GROUP, LLCADD458,289$673.7K
MAI Capital ManagementDOUBLED289,100$425.0K
NORTHERN TRUST CORPTRIM128,526$188.9K
CITADEL ADVISORS LLCNEAR_EXIT44,916$66.0K
OSAIC HOLDINGS, INC.ADD10,800$15.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 85% rate it Buy or better
Strong Buy5Buy6Hold1Sell1Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +860%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026Citizens
REITERATE
REITERATEMarket Outperform
Oct 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 7, 2026Brookline Capital
INITIATE
INITIATEBuy
May 5, 2026Citizens
INITIATE
INITIATEMarket Outperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 10, 2026
Faust Elizabeth
Director
AWARD196,299 sh
Apr 1, 2026
Erdtmann Rainer M
See Remarks
AWARD452,512 sh
Apr 1, 2026
Hitchcock Michael J.M.
Interim CEO
AWARD667,477 sh

Earnings setup

Estimates
Nov 3
reports in 7 days
−$0.22
EPS estimate, this quarter
+19%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.22-$0.28–-$0.17+0.0%$0.00
Next Q-$0.27-$0.47–-$0.17+0.0%$0.00
Current FY-$0.95-$1.37–-$0.64-12.5%$0.00
Next FY-$0.94-$1.40–-$0.50+0.0%$0.00
Reddit
Recent posts
r/pennystocks Neutral 13d ago
14 OCT 2026 , WHAT ARE THE BIGGEST LOSERS AND WHY ?
2 upvotes · 1 comments
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 13, 2026 SEC
Biomea Fusion reported Phase 1 topline data for BMF-650, its next-generation oral GLP-1 receptor agonist for obesity…
8-K — Impact 6/10
Oct 13, 2026 Press
Biomea Fusion announced Phase 1 data for oral GLP-1 RA BMF-650 showing 1.5%-3.2% weight reduction at Day 29 in…
Impact 5/10
Oct 13, 2026 FDA
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for
Sep 23, 2026 Press
Biomea Fusion terminated its proposed public offering due to unfavorable market conditions, with no securities sold…
Impact 5/10
Sep 22, 2026 SEC
Biomea Fusion is conducting a dilutive underwritten public offering of common stock and pre-funded warrants at an…
424B5 — Impact 6/10
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — TRIM
99 shares (—)
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — ADD
2,049,802 shares ($3.0M)
Jun 12, 2026 SEC
A mixed institutional cluster in BMEA for Q3 2024 shows 6 buyers (net +$2.9M) led by Marshall Wace doubling its stake…
INST-CLUSTER — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
BMEA Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Oct 13, 2026
FDA
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe or serious TEAEs, no...
Sep 23, 2026
Offering
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and…
Sep 22, 2026
Offering
Biomea Fusion Announces Proposed Public Offering of Securities
SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company…
Aug 31, 2026
Short interest
Short Interest: BMEA up 22% to 11.9M shares
Settlement 2026-08-31 | Days to cover: 4.96 | ≈16.49% of shares outstanding (est.)
Aug 28, 2026
Clinical Trial
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Phase 2 · COMPLETED

SecBot reports

7 filings · 7 press releases · 3 bullish · 1 bearish · 1 mixed · 2 neutral
All BMEA filing & press-release reports (14)